Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Table 3

Concomitant diseases in HER2-positive patients without adjuvant trastuzumab treatment.

	Premenopausal	Postmenopausal	All patients
Concomitant diseases, 𝑛 (%)	35 (14.8%)	202 (85.2%)	237 (100.0%)
Cardiopulmonary	12/35 (34.3%)	126/202 (62.4%)	138/237 (58.2%)
Gastrointestinal/hepatic/renal	—	10/202 (5.0%)	10/237 (4.2%)
Metabolic	7/35 (20.0%)	22/202 (10.9%)	29/237 (12.2%)
Mental	6/35 (17.1%)	15/202 (7.4%)	21/237 (8.9%)
Others	10/35 (28.6%)	29/202 (14.4%)	39/237 (16.5%)